Royalty Pharma Sub-Manager, LLC
NEW YORK, NY · Quarter end: Sep 30, 2026 · Filed with SEC: Nov 13, 2026 · Open the SEC source ↗
Portfolio Return (1Y)——
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.$196.3M2026 Q3
Positions4
Top-10 ConcentrationPercent of the portfolio in the 10 largest holdings. High means the fund is concentrated in few stocks.100.0%
Royalty Pharma Sub-Manager, LLC reported 4 positions worth $196.3M as of September 30, 2026 (13F filed November 13, 2026). Largest holding: CYTK (32.9%).
4 positions shown
Read the 2026-Q2 quarterly report · 13F Filing Calendar
Frequently Asked Questions
What stocks does Royalty Pharma Sub-Manager, LLC hold as of Q3 2026?
Royalty Pharma Sub-Manager, LLC reported 4 positions worth $196.3M in its Q3 2026 13F filing. Largest positions: CYTK (32.9%), ZBIO (32.8%), BHVN (20.0%) and KLRA (14.3%).
What did Royalty Pharma Sub-Manager, LLC buy in Q3 2026?
No previous quarter is available yet; the comparison appears with the next filing.
What did Royalty Pharma Sub-Manager, LLC sell in Q3 2026?
No previous quarter is available yet.
13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.